日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Gefapixant as a P2X3 receptor antagonist treatment for obstructive sleep apnea: a randomized controlled trial

吉法匹坦作为P2X3受体拮抗剂治疗阻塞性睡眠呼吸暂停:一项随机对照试验

Robbins, Jonathan A; Sands, Scott; Maganti, Lata; Crumley, Tami; Fox-Bosetti, Sabrina; Hussain, Azher; Schwartz, Howard; Safirstein, Beth; Ahmad, Maha; Dragone, Leonard; Nussbaum, Jesse; Kushida, Clete; Iwamoto, Marian; Stoch, S Aubrey

Population pharmacokinetic analysis of the P2X3-receptor antagonist gefapixant

P2X3受体拮抗剂吉法匹坦的群体药代动力学分析

Chawla, Akshita; Largajolli, Anna; Hussain, Azher; Kleijn, Huub; Ait-Oudhia, Sihem; Anton, Judith; Krishna Ananthula, Hari; Nussbaum, Jesse; La Rosa, Carmen; Gheyas, Ferdous

Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans

对吉法匹坦在人体内的吸收、代谢、排泄和质量平衡进行表征

Nussbaum, Jesse C; Hussain, Azher; Ma, Bennett; Min, K Chris; Chen, Qing; Tomek, Charles; Iwamoto, Marian; Stoch, S Aubrey

Assessment of Pharmacokinetic Interaction Between Gefapixant (MK-7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin

评估 P2X3 受体拮抗剂吉法匹坦 (MK-7264) 与 OATP1B1 药物转运体底物匹伐他汀之间的药代动力学相互作用

McCrea, Jacqueline B; Hussain, Azher; Ma, Bennett; Garrett, Graigory C; Evers, Raymond; Laabs, John E; Stoch, S Aubrey; Iwamoto, Marian

Clinical Formulation Bridging of Gefapixant, a P2X3-Receptor Antagonist, for the Treatment of Chronic Cough

临床制剂:P2X3受体拮抗剂吉法匹坦用于治疗慢性咳嗽的桥接

Gupta, Pranav; Hussain, Azher; Ford, Anthony P; Smith, Steven; Nussbaum, Jesse C; Stoch, Aubrey; Iwamoto, Marian

Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough

两项针对难治性或不明原因慢性咳嗽的P2X3受体拮抗剂gefapixant的3期随机对照试验(COUGH-1和COUGH-2)的设计和原理

Muccino, David R; Morice, Alyn H; Birring, Surinder S; Dicpinigaitis, Peter V; Pavord, Ian D; Assaid, Christopher; Kleijn, Huub Jan; Hussain, Azher; La Rosa, Carmen; McGarvey, Lorcan; Smith, Jaclyn A

Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.

tildrakizumab (MK-3222) 是一种高亲和力、选择性抗 IL23p19 单克隆抗体,对中重度银屑病患者细胞色素 P450 代谢的影响

Khalilieh Sauzanne, Hussain Azher, Montgomery Diana, Levine Vanessa, Shaw Peter M, Bodrug Inga, Mekokishvili Lally, Bailey-Smith Candice, Glasgow Xiaoli S, Cheng Amy, Martinho Monika, Iwamoto Marian